Bernard Banga

France

Author at BioWorld

Writer at BioWorld MedTech

Featured in: Favicon

bioworld.com

Articles

Real-time smartphone app from AI-Stroke uses AI to detect stroke

Sep 8, 2023 | bioworld.com | Bernard Banga

Real-time smartphone app from AI-Stroke uses AI to detect strokeAI-Stroke SAS is developing an artificial intelligence (AI)-based application able to detect strokes in real time using a simple smartphone or a tablet. The med-tech firm has just won an award in the i-Lab 2023 innovation competition, supported by the French Ministry of Research and sovereign bank Bpifrance SA.
Magenta Medical completes early feasibility study on miniature heart device

Sep 1, 2023 | bioworld.com | Bernard Banga

Vision for future in crisp HD as Regeneron regenerates with new Eylea winOn the heels of the U.S. FDA clearance for Veopoz (pozelimab-bbfg) from Regeneron Pharmaceuticals Inc. to treat Chaple disease, the regulatory rollercoaster ride...
Medalliance unveils drug-eluting balloon for dialysis complications

Aug 31, 2023 | bioworld.com | Bernard Banga

Medalliance SA reported completion of patient enrollment in the SAVE clinical trial with its Selution SLR 018 drug-eluting balloon. Eighty-four subjects have been recruited for this prospective multi-center, single-blinded, randomized controlled trial. These patients received either standard high-pressure balloon angioplasty followed by local application of Selution SLR, or else high-pressure balloon angioplasty with no further lesion treatment.
Cochlear and Sensorion combine drug and implant to enhance patient hearing

Aug 29, 2023 | bioworld.com | Bernard Banga

Viz.ai poised to take a bite out of hypertrophic cardiomyopathy with FDA de novoHypertrophic cardiomyopathy (HCM) might not be the talk of the town in the world of cardiology medical devices, but the condition has a devastating effect on a...
Cochlear and Sensorion combine drug and implant to enhance patient hearing

Aug 28, 2023 | bioworld.com | Bernard Banga

Cochlear and Sensorion combine drug and implant to enhance patient hearingCochlear Ltd. and Sensorion SA have published encouraging results on the combination of a molecule with a cochlear implant. Their proof-of-concept phase 2a study involved the combination of an orphan drug recognized in both Europe and the U.S. with cutting edge hearing aid implants to enhance the auditory capabilities of hearing aid users.
France overhauls framework for digital health app reimbursement

Aug 25, 2023 | bioworld.com | Bernard Banga

France overhauls framework for digital health app reimbursementThe French National Insurance Fund, known as La Caisse Nationale d’Assurance Maladie, a division reporting to the Ministry of Health and the Ministry of Economics and Finance in France, has released its annual report containing proposals aimed at achieving financial balance in the nation’s health insurance expenditures. The 100-page document will be submitted to the parliament to be voted upon this fall.
Safe Orthopaedics unveils promising device for vertebral compression fractures

Aug 23, 2023 | bioworld.com | Bernard Banga

Viz.ai poised to take a bite out of hypertrophic cardiomyopathy with FDA de novoHypertrophic cardiomyopathy (HCM) might not be the talk of the town in the world of cardiology medical devices, but the condition has a devastating effect on a...
Tandem Diabetes secures French reimbursement for semi-closed loop system

Aug 22, 2023 | bioworld.com | Bernard Banga

Tandem Diabetes secures French reimbursement for semi-closed loop systemTandem Diabetes Care Inc. obtained reimbursement in France for its Control-IQ technology, an advanced hybrid closed loop system for patients with type 1 diabetes that uses an algorithm to automatically adjust insulin in response to predicted glucose levels.
Fractus expands into health care with new wireless implanted device technology

Aug 21, 2023 | bioworld.com | Bernard Banga

Home » Fractus expands into health care with new wireless implanted device technology BioWorld briefs for Aug. 21, 2023. Investors have known for some time that the GLP-1 receptor agonist class offers tremendous promise for treating the underserved obesity population worldwide, but... Gracell Biotechnologies Inc. stands to gain up to $150 million from an assorted bouquet of private U.S. health care investors to lay a solid foundation for... Immuno-oncology company Imugene Ltd.
Amplifon secures $380M from EIB to drive audiology innovation

Aug 18, 2023 | bioworld.com | Bernard Banga

Amplifon secures $380M from EIB to drive audiology innovationAmplifon SpA has secured $380 million from the EU-backed European Investment Bank (EIB) to accelerate its innovation and digitalization process for its advanced hearing aid technology. “This loan guarantee confirms that we are on the right path towards innovation and digital transformation, which has Italy and the European Union as its starting point,” said Enrico Vita, CEO of Amplifon SpA. BioWorld MedTech Financings Europe